

## References

- Lukinmaa S, Nakari UM, Liimatainen A, Siitonen A. Genomic diversity within phage types of *Salmonella enterica* ssp. *enterica* serotypes Enteritidis and Typhimurium. *Foodborne Pathog Dis*. 2006;3:97–105. <http://dx.doi.org/10.1089/fpd.2006.3.97>
- Soyer Y, Moreno Switt A, Davis MA, Maurer J, McDonough PL, Schoonmaker-Bopp DJ, et al. *Salmonella enterica* serotype 4,5,12:1-, an emerging *Salmonella* serotype that represents multiple distinct clones. *J Clin Microbiol*. 2009;47:3546–56. <http://dx.doi.org/10.1128/JCM.00546-09>
- Sjölund-Karlsson M, Howie R, Krueger A, Rickert R, Pecic G, Lupoli K, et al. CTX-M–producing non-typhi *Salmonella* spp. isolated from humans, United States. *Emerg Infect Dis*. 2011;17:97–9. <http://dx.doi.org/10.3201/eid1701.100511>
- Rodríguez I, Barownick W, Helmuth R, Mendoza MC, Rodicio MR, Schroeter A, et al. Extended-spectrum  $\beta$ -lactamases and AmpC  $\beta$ -lactamases in ceftiofur-resistant *Salmonella enterica* isolates from food and livestock obtained in Germany during 2003–07. *J Antimicrob Chemother*. 2009;64:301–9. <http://dx.doi.org/10.1093/jac/dkp195>
- EFSA Panel on Biological Hazards (BIOHAZ). Scientific opinion on the public health risks of bacterial strains producing extended-spectrum  $\beta$ -lactamases and/or AmpC  $\beta$ -lactamases in food and food-producing animals. *EFSA Journal*. 2011;9:2322. <http://dx.doi.org/10.2903/j.efsa.2011.2322>
- Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing *Enterobacteriaceae*: an emerging public-health concern. *Lancet Infect Dis*. 2008;8:159–66. [http://dx.doi.org/10.1016/S1473-3099\(08\)70041-0](http://dx.doi.org/10.1016/S1473-3099(08)70041-0)
- Nyberg SD, Österblad M, Hakanen AJ, Huovinen P, Jalava J; The Finnish Study Group for Antimicrobial Resistance. Detection and molecular genetics of extended-spectrum beta-lactamases among cefuroxime-resistant *Escherichia coli* and *Klebsiella* spp. isolates from Finland, 2002–2004. *Scand J Infect Dis*. 2007;39:417–24. <http://dx.doi.org/10.1080/00365540601105731>
- Hakanen A, Kotilainen P, Huovinen P, Helenius H, Siitonen A. Reduced fluoroquinolone susceptibility in *Salmonella enterica* serotypes in travelers returning from Southeast Asia. *Emerg Infect Dis*. 2001;7:996–1003. <http://dx.doi.org/10.3201/eid0706.010613>
- Lindgren MM, Kotilainen P, Huovinen P, Hurme S, Lukinmaa S, Webber MA, et al. Reduced fluoroquinolone susceptibility in *Salmonella enterica* isolates from travelers, Finland. *Emerg Infect Dis*. 2009;15:809–12. <http://dx.doi.org/10.3201/eid1505.080849>
- Arlet G, Barrett TJ, Butaye P, Cloeckert A, Mulvey MR, White DG. *Salmonella* resistant to extended-spectrum cephalosporins: prevalence and epidemiology. *Microbes Infect*. 2006;8:1945–54. <http://dx.doi.org/10.1016/j.micinf.2005.12.029>
- CLSI. Performance standards for antimicrobial susceptibility testing: twentieth informational supplement. CLSI document M100–S20. Wayne (PA): Clinical Laboratory and Standards Institute; 2010.
- Jones CH, Ruzin A, Tuckman M, Visalli MA, Petersen PJ, Bradford PA. Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM- and SHV-type extended-spectrum  $\beta$ -lactamases in clinical isolates and identification of the novel  $\beta$ -lactamase genes *bla*<sub>SHV-48</sub>, *bla*<sub>SHV-105</sub>, and *bla*<sub>TEM-155</sub>. *Antimicrob Agents Chemother*. 2009;53:977–86. <http://dx.doi.org/10.1128/AAC.01155-08>
- Pérez-Pérez FJ, Hanson ND. Detection of plasmid-mediated AmpC beta-lactamase genes in clinical isolates by using multiplex PCR. *J Clin Microbiol*. 2002;40:2153–62. <http://dx.doi.org/10.1128/JCM.40.6.2153-2162.2002>
- Gunell M, Webber MA, Kotilainen P, Lilly AJ, Caddick JM, Jalava J, et al. Mechanisms of resistance in nontyphoidal *Salmonella enterica* strains exhibiting a nonclassical quinolone resistance phenotype. *Antimicrob Agents Chemother*. 2009;53:3832–6. <http://dx.doi.org/10.1128/AAC.00121-09>
- Tham J, Odenholt I, Walder M, Brolund A, Ahl J, Melander E. Extended-spectrum beta-lactamase-producing *Escherichia coli* in patients with travellers' diarrhoea. *Scand J Infect Dis*. 2010;42:275–80. <http://dx.doi.org/10.3109/00365540903493715>

Address for correspondence: Marianne Gunell, Medical Microbiology and Immunology, University of Turku, Kiinamylynkatu 13, FI-20520 Turku, Finland; email: marianne.gunell@utu.fi

## etymologia

### Artemisinin [ahr"tə-mis"i-nin]

**A**rtemisinin is an antimalarial lactone derived from *qing hao* (*Artemisia annua* or sweet wormwood). The medicinal value of this plant has been known to the Chinese for at least 2,000 years. In 1596, Li Shizhen recommended tea made from

*qing hao* specifically to treat malaria symptoms. The genus name is derived from the Greek goddess Artemis and, more specifically, may have been named after Queen Artemisia II of Caria, a botanist and medical researcher in the fourth century BCE.

### Sources

- Artemisia II. Encyclopaedia Britannica Online [cited 2014 Apr 17]. <http://www.britannica.com/EBchecked/topic/36829/Artemisia-II>
- Dorland's illustrated medical dictionary. 32nd ed. Philadelphia: Elsevier Saunders; 2012.
- Vinetz JM, Clain J, Bounkeua V, Eastman RT, Fidock D. Chemotherapy of malaria. In: Brunton LL, editors. Goodman & Gilman's the pharmacological basis of therapeutics. 12th ed. New York: The McGraw-Hill Companies, Inc; 2011. p. 1383–418.

Address for correspondence: Ronnie Henry, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Mailstop E03, Atlanta, GA 30333, USA; email: boq3@cdc.gov

DOI: <http://dx.doi.org/10.3201/eid2007.ET2007>